Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Progyny appoints Arielle Bogorad as VP, employer market strategy » 09:04
05/24/22
05/24
09:04
05/24/22
09:04
PGNY

Progyny

$34.70 /

-0.45 (-1.28%)

, CERN

Cerner

$94.09 /

+0.16 (+0.17%)

Progyny announced the…

Progyny announced the expansion of its leadership team. Arielle Bogorad, formerly from Cerner Corporation, will join Progyny as Senior Vice President of Employer Market Strategy. In Bogorad's new role, she will lead employer market strategy expanding relationships with Progyny's clients, strategic partners, and industry leaders. Bogorad joins Progyny after 13 years at Cerner Corporation, where she was most recently the Senior Director and Client General Manager of Workforce Health Services.

ShowHide Related Items >><<
PGNY Progyny
$34.70 /

-0.45 (-1.28%)

CERN Cerner
$94.09 /

+0.16 (+0.17%)

PGNY Progyny
$34.70 /

-0.45 (-1.28%)

12/01/21 Jefferies
Progyny initiated with a Buy at Jefferies
11/22/21 Citi
Progyny downgraded to Neutral from Buy at Citi
10/22/21 JPMorgan
Progyny price target raised to $79 from $65 at JPMorgan
09/30/21 Berenberg
Berenberg starts Progyny at Buy, sees 46% upside
CERN Cerner
$94.09 /

+0.16 (+0.17%)

04/11/22 Argus
Cerner downgraded to Hold from Buy at Argus
04/11/22 Argus
Cerner downgraded to Hold from Buy at Argus
01/06/22 Monness Crespi
Oracle selloff creates 'attractive buying opportunity,' says Monness Crespi
12/21/21 KeyBanc
Cerner downgraded to Sector Weight from Overweight at KeyBanc
PGNY Progyny
$34.70 /

-0.45 (-1.28%)

CERN Cerner
$94.09 /

+0.16 (+0.17%)

CERN Cerner
$94.09 /

+0.16 (+0.17%)

CERN Cerner
$94.09 /

+0.16 (+0.17%)

CERN Cerner
$94.09 /

+0.16 (+0.17%)

Earnings
Progyny raises FY22 EPS view to 7c-14c from (1c)-7c, consensus 12c » 17:14
05/05/22
05/05
17:14
05/05/22
17:14
PGNY

Progyny

$36.73 /

-3.33 (-8.31%)

Narrows FY22 revenue view…

Narrows FY22 revenue view to $735M-$775M from $730M-$775M, consensus $754.06M. The company said, "In light of our strong results in the first quarter, as well as our visibility into member utilization at this point, we are narrowing our guidance ranges by raising the lower end of our full year expectations."

ShowHide Related Items >><<
PGNY Progyny
$36.73 /

-3.33 (-8.31%)

PGNY Progyny
$36.73 /

-3.33 (-8.31%)

12/01/21 Jefferies
Progyny initiated with a Buy at Jefferies
11/22/21 Citi
Progyny downgraded to Neutral from Buy at Citi
10/22/21 JPMorgan
Progyny price target raised to $79 from $65 at JPMorgan
09/30/21 Berenberg
Berenberg starts Progyny at Buy, sees 46% upside
PGNY Progyny
$36.73 /

-3.33 (-8.31%)

Earnings
Progyny sees Q2 EPS 1c-2c, consensus 3c » 17:12
05/05/22
05/05
17:12
05/05/22
17:12
PGNY

Progyny

$36.73 /

-3.33 (-8.31%)

Sees Q2 revenue…

Sees Q2 revenue $188M-$193M, consensus $189.03M. "As the second quarter begins, the early indications of member activity have been consistent with our expectations, affirming - once again - the essential nature of fertility treatments and our members' resilience in pursuing care, even against the backdrop of a global pandemic," said Anevski.

ShowHide Related Items >><<
PGNY Progyny
$36.73 /

-3.33 (-8.31%)

PGNY Progyny
$36.73 /

-3.33 (-8.31%)

12/01/21 Jefferies
Progyny initiated with a Buy at Jefferies
11/22/21 Citi
Progyny downgraded to Neutral from Buy at Citi
10/22/21 JPMorgan
Progyny price target raised to $79 from $65 at JPMorgan
09/30/21 Berenberg
Berenberg starts Progyny at Buy, sees 46% upside
PGNY Progyny
$36.73 /

-3.33 (-8.31%)

Earnings
Progyny reports Q1 EPS 5c, consensus 1c » 17:10
05/05/22
05/05
17:10
05/05/22
17:10
PGNY

Progyny

$36.73 /

-3.33 (-8.31%)

Reports Q1 revenue…

Reports Q1 revenue $172.22M, consensus $167.18M. "We had a strong start to the year, achieving our highest-ever quarterly revenue, gross profit and Adjusted EBITDA, in addition to successfully launching with the largest number of new clients and covered lives in our history. We are also pleased to report that we continue to achieve industry-leading clinical outcomes. Across all measures, for the sixth straight year, we significantly outperformed as compared to the national averages released by the CDC," said Pete Anevski, CEO of Progyny. "Although we are in the earliest stages of our selling season, we are pleased with the level of sales and pipeline activity that we are seeing thus far, as every measure that we track is favorable to the record level of activity that we saw a year ago. In addition, we've also had a healthy number of early commitments and we continue to expect that the majority of client decisions will occur, as usual, in the late summer and early fall for implementations in 2023."

ShowHide Related Items >><<
PGNY Progyny
$36.73 /

-3.33 (-8.31%)

PGNY Progyny
$36.73 /

-3.33 (-8.31%)

12/01/21 Jefferies
Progyny initiated with a Buy at Jefferies
11/22/21 Citi
Progyny downgraded to Neutral from Buy at Citi
10/22/21 JPMorgan
Progyny price target raised to $79 from $65 at JPMorgan
09/30/21 Berenberg
Berenberg starts Progyny at Buy, sees 46% upside
PGNY Progyny
$36.73 /

-3.33 (-8.31%)

Hot Stocks
Progyny, RESOLVE to launch national infertility awareness week » 09:13
04/19/22
04/19
09:13
04/19/22
09:13
PGNY

Progyny

$41.53 /

-0.49 (-1.17%)

Progyny and RESOLVE: The…

Progyny and RESOLVE: The National Infertility Association announced both organizations will ring the Nasdaq Stock Market Opening Bell on Tuesday, April 26, 2022. The next day, on Wednesday, April 27, 2022, the partners will light the top of the Empire State Building, in orange, the official color for infertility awareness. The following evening, April 27, Progyny and RESOLVE will flip the ceremonial switch to light the top of the Empire State Building to recognize and give voice to the millions of people who struggle to build their families. "Progyny's mission is to make dreams of parenthood come true. As the fertility benefits provider of choice for hundreds of the world's leading brands and Fortune 500 companies, we have already helped more than 100,000 people on their family building journeys," said Pete Anevski, CEO of Progyny. "While National Infertility Awareness Week is only a seven-day period dedicated to the cause, we believe that the impact of our New York City takeover will echo across the country. We are honored to play a role in celebrating the strength of everyone who has struggled to build their families, during this week and always."

ShowHide Related Items >><<
PGNY Progyny
$41.53 /

-0.49 (-1.17%)

PGNY Progyny
$41.53 /

-0.49 (-1.17%)

12/01/21 Jefferies
Progyny initiated with a Buy at Jefferies
11/22/21 Citi
Progyny downgraded to Neutral from Buy at Citi
10/22/21 JPMorgan
Progyny price target raised to $79 from $65 at JPMorgan
09/30/21 Berenberg
Berenberg starts Progyny at Buy, sees 46% upside
PGNY Progyny
$41.53 /

-0.49 (-1.17%)

PGNY Progyny
$41.53 /

-0.49 (-1.17%)

Over a quarter ago
Conference/Events
Jefferies healthcare analyst to hold an analyst/industry conference call » 12:25
03/22/22
03/22
12:25
03/22/22
12:25
PGNY

Progyny

$50.21 /

+1.29 (+2.64%)

Healthcare Analyst…

Healthcare Analyst Santangelo, along with Sydni Meyrowitz, SVP of Strategy at Kindbody, discuss Progyny and the fertility benefits landscape on an Analyst/Industry conference call to be held on March 22 at 1 pm.

ShowHide Related Items >><<
PGNY Progyny
$50.21 /

+1.29 (+2.64%)

PGNY Progyny
$50.21 /

+1.29 (+2.64%)

12/01/21 Jefferies
Progyny initiated with a Buy at Jefferies
11/22/21 Citi
Progyny downgraded to Neutral from Buy at Citi
10/22/21 JPMorgan
Progyny price target raised to $79 from $65 at JPMorgan
09/30/21 Berenberg
Berenberg starts Progyny at Buy, sees 46% upside
PGNY Progyny
$50.21 /

+1.29 (+2.64%)

PGNY Progyny
$50.21 /

+1.29 (+2.64%)

Conference/Events
Jefferies healthcare analyst to hold an analyst/industry conference call » 10:37
03/22/22
03/22
10:37
03/22/22
10:37
PGNY

Progyny

$50.58 /

+1.655 (+3.38%)

Healthcare Analyst…

Healthcare Analyst Santangelo, along with Sydni Meyrowitz, SVP of Strategy at Kindbody, discuss Progyny and the fertility benefits landscape on an Analyst/Industry conference call to be held on March 22 at 1 pm.

ShowHide Related Items >><<
PGNY Progyny
$50.58 /

+1.655 (+3.38%)

PGNY Progyny
$50.58 /

+1.655 (+3.38%)

12/01/21 Jefferies
Progyny initiated with a Buy at Jefferies
11/22/21 Citi
Progyny downgraded to Neutral from Buy at Citi
10/22/21 JPMorgan
Progyny price target raised to $79 from $65 at JPMorgan
09/30/21 Berenberg
Berenberg starts Progyny at Buy, sees 46% upside
PGNY Progyny
$50.58 /

+1.655 (+3.38%)

PGNY Progyny
$50.58 /

+1.655 (+3.38%)

Earnings
Progyny sees FY22 EPS (1c)-7c, consensus 55c » 17:43
02/28/22
02/28
17:43
02/28/22
17:43
PGNY

Progyny

$39.35 /

+0.72 (+1.86%)

Sees FY22 revenue…

Sees FY22 revenue $730M-$775M, consensus $758.84M. Sees FY22 adjusted EBITDA $110M-$122M.

ShowHide Related Items >><<
PGNY Progyny
$39.35 /

+0.72 (+1.86%)

PGNY Progyny
$39.35 /

+0.72 (+1.86%)

12/01/21 Jefferies
Progyny initiated with a Buy at Jefferies
11/22/21 Citi
Progyny downgraded to Neutral from Buy at Citi
10/22/21 JPMorgan
Progyny price target raised to $79 from $65 at JPMorgan
09/30/21 Berenberg
Berenberg starts Progyny at Buy, sees 46% upside
PGNY Progyny
$39.35 /

+0.72 (+1.86%)

PGNY Progyny
$39.35 /

+0.72 (+1.86%)

Earnings
Progyny sees Q1 EPS (2c)-(1c), consensus 16c » 17:41
02/28/22
02/28
17:41
02/28/22
17:41
PGNY

Progyny

$39.35 /

+0.72 (+1.86%)

Sees Q1 revenue…

Sees Q1 revenue $165M-$170M, consensus $180.25M. Sees Q1 adjusted EBITDA $23.5M-$24.5M.

ShowHide Related Items >><<
PGNY Progyny
$39.35 /

+0.72 (+1.86%)

PGNY Progyny
$39.35 /

+0.72 (+1.86%)

12/01/21 Jefferies
Progyny initiated with a Buy at Jefferies
11/22/21 Citi
Progyny downgraded to Neutral from Buy at Citi
10/22/21 JPMorgan
Progyny price target raised to $79 from $65 at JPMorgan
09/30/21 Berenberg
Berenberg starts Progyny at Buy, sees 46% upside
PGNY Progyny
$39.35 /

+0.72 (+1.86%)

PGNY Progyny
$39.35 /

+0.72 (+1.86%)

Hot Stocks
Progyny reports Q4 EPS 15c, consensus 4c » 17:39
02/28/22
02/28
17:39
02/28/22
17:39
PGNY

Progyny

$39.35 /

+0.72 (+1.86%)

Reports Q4 revenue…

Reports Q4 revenue $127.55M, consensus $136.08M. "While member utilization for October and November was strong and consistent with our expectations, the emergence and rapid spread of the COVID-19 Omicron variant affected activity in December and January," said Pete Anevski, CEO of Progyny. "As the effects of the Omicron wave began to subside, we saw our members return to care at more typical levels starting in February, demonstrating yet again the continued resilience of fertility patients in their pursuit of care, even against the backdrop of a global pandemic."

ShowHide Related Items >><<
PGNY Progyny
$39.35 /

+0.72 (+1.86%)

12/01/21 Jefferies
Progyny initiated with a Buy at Jefferies
11/22/21 Citi
Progyny downgraded to Neutral from Buy at Citi
10/22/21 JPMorgan
Progyny price target raised to $79 from $65 at JPMorgan
09/30/21 Berenberg
Berenberg starts Progyny at Buy, sees 46% upside
PGNY Progyny
$39.35 /

+0.72 (+1.86%)

PGNY Progyny
$39.35 /

+0.72 (+1.86%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.